Enicepatide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Enicepatide is Roche's weekly shot that works on GLP-1 and GIP. In a 48-week mid-stage study, people on the top dose lost 22.5 percent more weight than on a dummy shot. Large final-stage studies start in 2026.
Evidence grade for Enicepatide: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 0 people given it
1 effects reported, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Enicepatide is a weekly shot from Roche. It works on two hunger signals, GLP-1 and GIP, like Mounjaro. It is built to keep working longer at the receptor. It is not approved. Large final-stage studies start in 2026.
What people take it for
- Big weight loss.
- Getting blood sugar back to normal in prediabetes.
What studies in people showed
The main study had 469 adults and ran 48 weeks. On the top dose, people ended up 22.5 percent lighter than the dummy group. Weight was still falling. About one in four lost 30 percent or more of their weight. Of those who started with prediabetes, 73 percent were back to normal blood sugar. These results came from Roche and a short meeting summary. There is no full paper yet.
What people report
Reports, not study results
The good
- In the studies on this page, about one person in four lost 30 percent or more of their weight.
The bad
- The reports on this page do not list side effects, and we have not collected user reports on this one yet.
Where these come from: The good line is from the company release and study summaries on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Losing a third of your weight is huge. Losing muscle along with it would be a disaster. If you ever use drugs like this, lift heavy and eat your protein.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Enicepatide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 2 studies
35 of the 36 indexed goals have no study of any kind behind Enicepatide
No study in people, animals or cells on this page reports a result for these. That does not prove Enicepatide does nothing for them. It does mean anything you have heard about Enicepatide and one of these did not come from a study cited here.
Show full evidence
What is Enicepatide?
Enicepatide is Roche's weekly shot that works on GLP-1 and GIP. In a 48-week mid-stage study, people on the top dose lost 22.5 percent more weight than on a dummy shot. Large final-stage studies start in 2026.
Enicepatide came to Roche when it bought Carmot Therapeutics. It works on two appetite signals, GLP-1 and GIP. It is built to favour one signal inside the cell, and to keep the receptor from being pulled inside, which the company says keeps it working longer. In a mid-stage study of 469 people, reported in January 2026, the 24 mg dose took off 22.5 percent more weight than a dummy shot at 48 weeks, and weight was still falling. About one in four people lost 30 percent or more of their weight. Of those who started with prediabetes, 73 percent were back to normal blood sugar. Large final-stage studies, called Enith, follow in 2026.
How does Enicepatide work?
It turns on both the GLP-1 and GIP signals. It is built to push the cAMP signal inside the cell, and to limit the process that pulls receptors inside and switches them off.
The evidence, in charts
Fig. 1a · how many people
3studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 3 sources here are studies in people.
- Study in people · done in people3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Enicepatide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Roche reports 48-week Phase 2 results for CT-388 in obesity
People on the top dose lost a lot of weight. 469 adults took weekly enicepatide or a dummy shot for 48 weeks. On the top dose the average person ended up about 22 percent lighter than the dummy group, and weight was still falling when the study stopped. These numbers came from Roche's own announcement first. This was a mid-stage study, so the large studies that decide approval are still ahead.
22.5% placebo-adjusted weight loss at 48 weeks on 24 mg.
- Study in people2026CT-388 Phase 2 in adults with obesity
About one person in four lost at least a third of their body weight. That is surgery territory, reached with a weekly injection over 48 weeks. The figure describes the share of people who hit that mark, not the average, and the average across everyone was lower. It comes from a mid-stage trial of a few hundred people. Nobody yet knows how many keep that weight off after stopping.
26.1% of participants lost 30% or more of body weight.
- Study in people20262813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study
Most people in the study who had early blood sugar trouble no longer had it by the end. Among those who started with prediabetes, roughly three in four were back in the normal range after 48 weeks. This was reported as a conference abstract, which is a short summary rather than a full paper. Prediabetes also improves with weight loss alone, so this cannot separate the drug from the pounds lost.
73% of participants with prediabetes normalized glucose.
Where to buy Enicepatide
No seller we track lists Enicepatide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Enicepatide been tested in people?
Yes. 0 people given it across 2 completed trials cited here, 0 of which found nothing. Enicepatide is Roche's weekly shot that works on GLP-1 and GIP. In a 48-week mid-stage study, people on the top dose lost 22.5 percent more weight than on a dummy shot. Large final-stage studies start in 2026.
What is the Enicepatide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 0 people given it
Is Enicepatide FDA-approved?
Investigational; final-stage studies (Enith 1 and 2) starting 2026
What does 'biased agonist' mean here?
The drug is built to set off one signal inside the cell, called cAMP, more than a second route that pulls the receptor into the cell. The aim is an effect that lasts longer. Whether that makes any real difference compared with tirzepatide is not proven.
Latest reading on Enicepatide
Blog posts about Enicepatide, newest first.